News >

KD025 Induces Impressive Activity in cGVHD

Audrey Sternberg
Published: Monday, Feb 24, 2020

Corey S. Cutler, MD, MPH, of the Dana-Farber Cancer Institute

Corey S. Cutler, MD, MPH

The selective ROCK2 inhibitor KD025 induced clinical responses in approximately two-thirds of patients with chronic graft-versus-host disease (cGVHD), including complete responses in 3 patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication